Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Atossa Therapeutics, Inc. (ATOS) had Consolidated Net Income/Loss of $-8.49M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-8.49M |
|
-- |
|
-- |
|
$8.69M |
|
$-8.69M |
|
$0.20M |
|
$-8.49M |
|
$-8.49M |
|
$-8.49M |
|
$-8.49M |
|
|
Consolidated Net Income/Loss |
$-8.49M |
$-8.49M |
|
$-8.69M |
|
$-8.69M |
|
8.91M |
|
8.91M |
|
$-0.95 |
|
$-0.95 |
|
| Balance Sheet Financials | |
$31.01M |
|
-- |
|
$1.27M |
|
$32.28M |
|
$5.45M |
|
-- |
|
-- |
|
$5.45M |
|
$26.83M |
|
$26.83M |
|
$26.83M |
|
8.61M |
|
| Cash Flow Statement Financials | |
$-19.23M |
|
-- |
|
$4.02M |
|
$41.41M |
|
$26.20M |
|
$-15.21M |
|
$1.54M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.69 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-19.23M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-31.65% |
|
-31.65% |
|
-26.30% |
|
-31.65% |
|
$3.12 |
|
$-2.16 |
|
$-2.16 |
|